IN.PACT™ 018 Drug-Coated Balloon (DCB)

Contact us

Choose the low-profile DCB with trusted technology and designed for better deliverability.*

IN.PACT 018 DCB combines a low-profile design and proven technology to deliver lasting results to your patients with femoropopliteal disease. 

Anatomy illustration with text callouts about new 0.18 inch DCB platform
Electric blue illustration showing lesion interfering with blood flow in a vessel on transparent background

Engineered to cross tight lesions and provide better deliverability*

 Decorative element

5 Fr compatible
(4–6 mm diameter)

Electric blue illustration of a drug-coated balloon and catheter on a transparent background

130 and 200 cm catheter lengths provide the option of transradial or femoral access

Electric blue illustration of IN.PACT Admiral drug-coated balloon on a transparent background

Uses the same proven formulation as IN.PACT™ Admiral™, the DCB physicians choose the most

   

Features

IN.PACT 018 DCB and catheter with circular numbers 1–4 as callouts

  

  1. Platinum-iridium marker bands
  2. Coaxial shaft
  3. FreePac coating
  4. 130 and 200 cm catheter lengths

Peel-away balloon protector

The IN.PACT 018 DCB features a peel-away balloon protector that helps preserve the integrity of the drug coating.

Illustration of peel away balloon protector feature on IN.PACT 018 DCB

Building on proven technology

The IN.PACT 018 DCB brings the proven formulation of the IN.PACT Admiral DCB to a new platform, so interventionalists can expect the same sustained efficacy and safety.

Watch this mechanism of action animation to see what makes IN.PACT DCBs unique.

Expanded platform, trusted data

The Medtronic IN.PACT 018 and IN.PACT Admiral DCBs allow you to choose your preferred tool knowing you're using DCBs backed by unmatched safety and efficacy data1 — including five-year data on complex lesions.2

With 75% of patients remaining reintervention-free at five years,1 IN.PACT Admiral has the:

  • Highest patency benefit through three years1
  • Lowest CD-TLR rate through five years1
  • Most publications for a DCB

The safety and effectiveness of the IN.PACT Admiral DCB (.035 in guidewire compatible), as established in the clinical studies that were performed primarily via femoral access, can be considered supportive for the IN.PACT 018 DCB. The IN.PACT 018 DCB has not been evaluated in a clinical study.

Outcomes Protection Program

Backed by proven technology, the IN.PACT Admiral and IN.PACT 018 DCB Outcomes Protection Program is one of the ways we are partnering with you to improve patient outcomes, manage costs, and take value-based healthcare.

We’re so confident in our clinical outcomes that we will share in the cost of care if your patients require reintervention within one year of treatment.

How the program works

 Decorative element

Treat

Treat your patient with IN.PACT Admiral DCB or IN.PACT 018 DCB according to the IFU.

 Decorative element

Qualifying event

If your patient returns for a qualifying reintervention within one year, your facility is eligible for a rebate.

 Decorative element

Rebate

Simply submit the claim form within 30 days of the secondary intervention, and Medtronic will provide a $1,000 rebate to share in the cost of care. 

Contact information

CardioVascular Lifeline Customer Support
763-526-7890
rs.cstechsupport@medtronic.com

24-hour technical support (worldwide)
763-514-4000

The safety and effectiveness of the IN.PACT Admiral DCB (.035 in guidewire compatible), as established in the clinical studies that were performed primarily via femoral access, can be considered supportive for the IN.PACT 018 DCB. The IN.PACT 018 DCB has not been evaluated in a clinical study.

*

Data on file with Medtronic.

Publications on file with Medtronic.

Some restrictions may apply.

References

1

Laird JA, Schneider PA, Jaff MR, et al. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. 5-year results from the IN.PACT SFA Trial. Circ Cardiovasc Interv. June 2019;12(6):e007702.

2

Tepe G. 5-year results from the IN.PACT Global Study Prespecified Cohorts: ISR, CTO and Long Lesions. Presented at VIVA 2021.